Project Grant R01CA309099
Award Date 8/3/26
Completion Date 7/31/31
Dollars Obligated $757K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $199,694 in project grant funding on August 18, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and test PROSPER, a resilience-promoting mobile health intervention designed to prevent chronic postsurgical pain in patients undergoing gynecologic oncology surgery. The award funds development of a perioperative psychological intervention adapted from Pain Coping and Resilience Therapy (PCRT),...
- The National Institute of General Medical Sciences awarded Brigham and Women's Hospital $445,983 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support cellular therapy research for sepsis and lung injury. The funded work investigates mesenchymal stem/stromal cells and placenta-derived trophoblast stem cells as therapeutic interventions in preclinical models of sepsis and acute lung injury. The laboratory examines mechanisms of biological...
- This $1,428,720.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Brigham & Women's Hospital Inc. to investigate the degradation of the menin/KMT2A protein complex for the treatment of myeloid neoplasms. The 4-year project, running from August 1, 2025 to July 31, 2029, aims to advance scientific understanding and develop potential new therapeutic approaches for these blood cancers. As a...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
- The National Cancer Institute awarded Brigham & Women's Hospital Inc. $409,463 on June 16, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate eukaryotic translation initiation factor 4A (EIF4A) inhibition as a therapeutic approach for acute myeloid leukemia. The research validates zotatifin, a clinical-grade EIF4A inhibitor, as a small molecule to target AML cells. The central hypothesis is that zotatifin selectively targets AML cells over healthy cells and...
- The National Cancer Institute awarded Brigham & Women's Hospital $772,208 on April 10, 2026, under Cancer Treatment Research (CFDA 93.395) to conduct macrophage-directed strategies for BRCA-associated breast cancer treatment, with performance through March 31, 2031. The recipient is characterizing tumor microenvironment responses to combined PARP inhibition (olaparib) and anti-CSF-1R antibody (axatilimab) therapy in patients enrolled in the AXALAP clinical trial. Work includes analysis of...
- The National Cancer Institute awarded The MGH Institute of Health Professions, Inc. $696,498 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention for improving functional recovery and participation in life roles among breast cancer survivors. The research uses the Multiphase Optimization Strategy (MOST) framework to systematically test three remotely delivered intervention components: priority elicitation to...
- The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $588,606 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a multisite randomized efficacy trial of STRIDE, an evidence-based telehealth intervention for improving symptom management and medication adherence in patients with hormone-sensitive breast cancer receiving...
- The National Institutes of Health's National Cancer Institute awarded $331,085.91 under the Cancer Research Manpower federal grant program (CFDA 93.398) to Brigham & Women's Hospital Inc. on February 1, 2021 for completion by September 30, 2022. The project grant funding will support research investigating the role of cellular senescence in chemotherapy-related cognitive impairment and the contribution of microglia to chemotherapy-induced senescence in the brain. Specifically, the grantee...